Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | CTSE | P14091 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | STS | P08842 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16874679 | 0.95 | ALDH1A1 (0.51) | ALDH1A1BACE1CTSDCTSESMN1; SMN2 | |
| SCHEMBL6159582 | 0.93 | LMNA (0.49) | ALDH1A1BACE1CTSDCTSESMN1; SMN2 | |
| SCHEMBL7967262 | 0.89 | ALDH1A1 (0.49) | ALDH1A1BACE1CTSDCTSESMN1; SMN2 | |
| SCHEMBL3138690 | 0.86 | GPR119 (0.46) | ALDH1A1BACE1CTSDCTSEGPR119 | |
| SCHEMBL16874872 | 0.86 | ALDH1A1 (0.51) | ALDH1A1BACE1CTSDCTSESMN1; SMN2 | |
| SCHEMBL18432250 | 0.86 | ESR2 (0.48) | ALDH1A1SMN1; SMN2GPR119OPRD1OPRK1 | |
| SCHEMBL11956931 | 0.86 | GPR119 (0.53) | SMN1; SMN2GPR119OPRM1OPRD1OPRK1 | |
| SCHEMBL3044892 | 0.86 | PARP10 (0.51) | GPR119OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3396946 | 0.86 | GPR119 (0.54) | ALDH1A1BACE1CTSDCTSEGPR119 | |
| SCHEMBL13908097 | 0.85 | BACE1 (0.55) | ALDH1A1BACE1CTSDCTSESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200297742-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200297742-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3677578-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Bristol-Myers Squibb Company (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3677578-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Bristol-Myers Squibb Company (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314392-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-8258156-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-09-04 | — | — | US | disclosed |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC, a Delaware Limited Company (BM) | 2011-09-15 | — | — | US | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314392-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GRIN2C, GRIN3A, GRIN2B | ALDH1A1 848/4885BACE1 1170/4885CTSD 4190/4885 |
| US-20200297742-A1 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GRIN2C, GRIN3A, GRIN2B | ALDH1A1 848/4885BACE1 1170/4885CTSD 4190/4885 |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | ALDH1A1 2341/4885BACE1 2310/4885CTSD 1812/4885 |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885BACE1 1128/4885CTSD 4104/4885 |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885BACE1 1128/4885CTSD 4104/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885BACE1 1128/4885CTSD 4104/4885 |
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | ALDH1A1 201/4885BACE1 2205/4885CTSD 2085/4885 |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | ALDH1A1 2341/4885BACE1 2310/4885CTSD 1812/4885 |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885BACE1 1128/4885CTSD 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.